Researchers at Biodol Therapeutics SAS, Centre National de la Recherche Scientifique, INSERM and Université de Strasbourg have divulged new n-heteroarylbenzamide derivatives acting as FLT3 (FLK2/STK1) inhibitors and reported to be useful for the treatment of pain.